Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cancer Causing...

    Cancer Causing Asbestos Threat: Sri Lanka halts imports of Johnson & Johnson Baby Powder

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-02-01T12:51:45+05:30  |  Updated On 17 Aug 2021 10:13 AM IST

    COLOMBO (Reuters) - Sri Lanka has halted imports of Johnson & Johnson Baby Powder until the company proves its product is free from cancer-causing asbestos, two government officials and the product's local distributor told Reuters.


    Stocks of the product already in Sri Lanka can still be sold, but there will be no new imports of the talc, a popular healthcare product across Sri Lanka and much of Asia, until J&J India, from where Sri Lanka imports the product, provides fresh test results.


    Read Also: Johnson and Johnson settles case in U.S for $120 million

    On Dec. 14, Reuters reported that the U.S. drugs and consumer products group knew for decades that asbestos lurked in its Baby Powder, leading to tests in several countries, including in India.


    The report was based on thousands of pages of company memos, internal reports, and other confidential documents.


    J&J has described the Reuters story as "one-sided, false, and inflammatory".


    Kamal Jayasinghe, chief executive of Sri Lanka's National Medicine Regulatory Authority (NMRA), which is part of the health ministry, said it had informed the distributor, A.Baur & Co., that it would require further tests for it to continue importing the powder.


    Read Also: Johnson & Johnson profit beats, lifts forecast on cancer drug demand
    asbestos lurkedasbestos testscancercancer causing asbestosHealth MinistryHealthcareHealthcare (TRBC)IndiaJohnsonJohnson & JohnsonKamal JayasingheNational Medicine Regulatory AuthorityNMRASri LankaUnited StatesUS
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok